Saturday 17 October 2026 Export NNOX’s income statement to Excel — free account

Nano-X Imaging Ltd.

Nano-X Imaging Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 15.4% from fiscal 2024. In the quarter to June 2026, revenue grew 36.7%, EPS fell 243.5%, free cash flow fell 21.4% and total debt fell 12.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

0.45 0.04 −8.16%

Follow NNOX

Alert me

Market cap: $38.6M
P/E: 0.0×
Fwd P/E: −2.9×
Dividend yield: —
F-score: 3/9
Altman Z: −0.16
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.18

Total sells 0.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	3	1	3	—
Sell	—	—	—	—	—	—	—	1	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 38.60

Revenue 15.63

Net Income (116.81)

Free Cash Flow (52.09)

Net Debt (28.10)

Current Ratio 2.84

Debt/Equity 0.04

P/E ratio 0.00

Fwd P/E (2.91)

P/S ratio 2.01

P/B ratio 0.43

Past 5Y EPS Growth —

This Y EPS Growth (8.91%)

Next Y EPS Growth 64.12%

Next Y revenue growth 71.03%

Next 5Y EPS Growth 38.74%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.10%

10-year low 10-year high

P/B against its own 10 years 0.06%

10-year low 10-year high

EV/Sales against its own 10 years 0.10%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	82	58	49	31
Receivables	1	2	2	2
Inventory	2	1	3	3
Other	1	17	11	2
	89	79	67	39

	2023	2024	2025	Q'26
Payables	3	2	3	2
ST’ Debt	3	3	3	3
Other	3	4	5	4
	16	14	17	14

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	14.93%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(9.55%)	(13.60%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	4	4	—	—	—
’25	3	3	3	4	13
’24	3	3	3	3	11
’23	2	3	2	2	10
’22	2	2	2	2	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(14)	(12)	—	—	—
’25	(10)	(9)	(11)	(10)	(41)
’24	(9)	(8)	(8)	(11)	(37)
’23	(11)	(10)	(11)	(13)	(45)
’22	(11)	(10)	(8)	(15)	(43)
’21	(4)	(7)	(7)	(19)	(38)
’20	0	0	(8)	(13)	(21)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(13)	—	—	—
’25	(11)	(10)	(12)	(11)	(45)
’24	(10)	(9)	(9)	(12)	(39)
’23	(12)	(10)	(12)	(13)	(48)
’22	(15)	(12)	(9)	(14)	(51)
’21	(10)	(14)	(12)	(25)	(61)
’20	0	0	(10)	(26)	(35)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.20)	(0.79)	—	—	—
’25	(0.21)	(0.23)	(0.21)	(0.50)	(1.16)
’24	(0.21)	(0.23)	(0.23)	(0.23)	(0.91)
’23	(0.21)	(0.31)	(0.37)	(0.18)	(1.08)
’22	(0.41)	(0.38)	(0.37)	(0.86)	(2.01)
’21	(0.27)	(0.28)	(0.28)	(0.44)	(1.26)
’20	(0.26)	(0.22)	(0.29)	(0.46)	(1.23)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	20.26	13.90	6.41	4.89	5.26	2.76	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	69.18	94.81	16.44	22.69	14.28	11.00
People
People	Employees	—	—	—	21	50	186	180	164	165	197
	Revenue/emp, $m	—	—	—	0.00	0.00	0.01	0.05	0.06	0.07	0.07
Income, $m
Income, $m	Revenue	—	—	—	—	—	1	9	10	11	13
	Gross margin, %	—	—	0.00	0.00	0.00	(115.95)	(80.21)	(66.55)	(94.03)	(98.21)
	EBT	—	—	(2)	(23)	(44)	(62)	(117)	(61)	(54)	(77)
	EBT margin, %	—	—	0.00	0.00	0.00	(4,742.79)	(1,363.03)	(617.01)	(477.48)	(589.89)
	Net income	—	0	(2)	(23)	(44)	(62)	(113)	(61)	(54)	(75)
	Depreciation	—	—	0	0	0	2	64	20	11	12
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.03	0.16	0.18	0.19	0.20
	Earnings	—	—	(0.09)	(0.90)	(1.23)	(1.26)	(2.01)	(1.08)	(0.91)	(1.16)
	Cash flow	—	—	(0.18)	(0.22)	(0.60)	(0.79)	(0.83)	(0.79)	(0.62)	(0.63)
	Capex	—	—	0.00	0.00	(0.39)	(0.48)	(0.14)	(0.06)	(0.05)	(0.06)
	Free cash flow	—	—	(0.18)	(0.22)	(0.99)	(1.27)	(0.97)	(0.85)	(0.67)	(0.69)
	Book value	—	—	(0.31)	(0.35)	6.47	6.06	4.15	3.47	3.22	2.16
	Shares, m	—	—	21	25	36	48	52	56	59	65
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	0.00	43.42	36.76	37.44	13.93
	P/B	—	—	—	—	—	2.40	1.72	1.86	2.23	1.30
	EV/Sales	—	—	—	—	—	0.00	34.86	29.13	32.89	10.66
	EV/FCF	—	—	—	—	—	(10.07)	(5.91)	(6.00)	(9.43)	(3.08)
Cash, $m
Cash, $m	Operating cash flow	—	—	(4)	(6)	(21)	(38)	(43)	(45)	(37)	(41)
	Capex	—	—	0	0	(14)	(23)	(7)	(3)	(3)	(4)
	Free cash flow	—	—	(4)	(6)	(35)	(61)	(51)	(48)	(39)	(45)
Balance, $m
Balance, $m	Working capital	—	—	(7)	(11)	215	42	57	73	65	50
	Total debt	—	—	—	1	1	4	4	3	3	3
	Net debt	—	—	0	(8)	(212)	(85)	(73)	(79)	(55)	(46)
	Shareholders’ equity	—	—	(6)	(9)	231	292	217	196	189	140
Returns, %
Returns, %	ROA	—	—	(205.82)	(328.76)	(35.33)	(20.62)	(36.70)	(25.72)	(24.97)	(40.31)
	ROIC	—	—	0.00	0.00	(146.64)	(18.55)	(51.35)	(33.56)	(26.37)	(52.17)
	ROE	—	—	25.18	297.63	(39.48)	(23.64)	(44.51)	(29.49)	(27.83)	(45.62)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SRTS Sensus Healthcare, Inc.	$45.6M	— (loss-making)	— (loss-making)	−68.69% (below 0%: shrinking)	n/m	−201.65% (below 0%: shrinking)	33.58%	(138.86%)	Compare
TELA TELA Bio, Inc.	$45.6M	— (loss-making)	— (loss-making)	−4.49% (below 0%: shrinking)	n/m	−17.72% (below 0%: shrinking)	72.77%	(48.12%)	Compare
SNWV Sanuwave Health Inc.	$44.5M	3.0×	— (loss-making)	−3.13% (below 0%: shrinking)	n/m	+86.75% (above 0%: growing)	76.23%	(2.88%)	Compare
XTNT Xtant Medical Holdings, Inc.	$42.5M	— (loss-making)	— (loss-making)	−34.96% (below 0%: shrinking)	n/m	−881.96% (below 0%: shrinking)	57.88%	(39.81%)	Compare
RPID Rapid Micro Biosystems, Inc.	$42.4M	— (loss-making)	— (loss-making)	+10.91% (above 0%: growing)	n/m	−23.97% (below 0%: shrinking)	15.05%	(152.99%)	Compare
NNOX Nano-X Imaging Ltd.	$38.6M	— (loss-making)	— (loss-making)	+36.71% (above 0%: growing)	n/m	−21.37% (below 0%: shrinking)	(1,050.87%)	(1,334.91%)
CVRX CVRx, Inc.	$37.0M	— (loss-making)	— (loss-making)	+15.57% (above 0%: growing)	n/m	−11.18% (below 0%: shrinking)	87.39%	(82.92%)	Compare
ELUT Elutia Inc.	$34.9M	0.6×	— (loss-making)	−11.65% (below 0%: shrinking)	n/m	−2.52% (below 0%: shrinking)	59.62%	(327.85%)	Compare
QTI QT Imaging Holdings, Inc.	$34.8M	— (loss-making)	— (loss-making)	+103.20% (above 0%: growing)	n/m	−236.31% (below 0%: shrinking)	41.16%	(25.07%)	Compare
Median of peers	$42.4M	—	—	−3.81%	—	−20.84%	58.75%	(65.52%)

All 149 Medical Devices stocks →

Nano-X Imaging Ltd. (NNOX) key facts

Strength: Nano-X Imaging Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 15.4% from fiscal 2024.
Nano-X Imaging Ltd. (NNOX) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NNOX traded at $0.45, a market capitalization of $38.6 million.
Return on equity was −45.6% and debt-to-equity 0.04.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −0.16 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.